XenoGesis invests in LC-MS/MS machine

A significant investment has been made by drug metabolism and pharmacokinetics (DMPK) business XenoGesis in a brand new LC-MS/MS machine, bringing the company's total number of mass spec machines at its BioCity base to three.

Scheduled for installation in August, The Waters Xevo TQ-S micro with ACQUITY I-class will increase capacity by around 50% as well as add a new range of capabilities. This will open up new avenues for XenoGesis, broadening the number of clients and types of projects that can be supported.

XenoGesis founder and managing director Dr. Richard Weaver said: “This is a significant move for us. Bringing in this new technology enhances our capabilities and increases our capacity. Having the new LC-MS/MS machine in place will help to differentiate us further.”

The investment has been supported by a grant secured from Invest to Grow, managed by the University of Derby, which will provide just under a third of the funds needed.

“Investment is extremely important to XenoGesis. Ensuring we have the latest, cutting-edge technology for the benefit of client projects will improve efficiency, speed and provide ultimate sensitivity. Whilst are extremely grateful for the support from the Invest to Grow programme.”

The University’s head of strategic programmes David Harper said: “We are delighted to support the growth plans of XenoGesis. The funding will allow the company to invest in important capital equipment, and will lead directly to the creation of high quality jobs”.

The new equipment comes at a time when specialist DMPK and pharmacokinetic business XenoGesis has announced record growth, with turnover exceeding the £1m mark in just over three years.